文献速递乳腺MR

乳腺背景实质强化作为激素受体阳性、HER2阴性乳腺癌无浸润性疾病生存的预测因素

Background parenchymal enhancement as a predictor of invasive disease-free survival in hormone receptor-positive, HER2-negative breast cancer.
PubMed 文献 · Eur J Radiol · 2025-07-26

单中心回顾性研究纳入2190例激素受体阳性、HER2阴性且无腋窝淋巴结转移的乳腺癌女性,评估背景实质强化(BPE)与临床病理因素对无浸润性疾病生存(iDFS)的预测价值,并与Oncotype DX复发评分比较。BPE是iDFS的独立预测因素,含BPE的组合模型对5年iDFS的区分度优于临床病理模型和Oncotype DX复发评分。

要点

  • BPE是激素受体阳性、HER2阴性、腋窝淋巴结阴性乳腺癌iDFS的独立预测因素。
  • 含BPE的组合模型预测5年iDFS的AUROC为0.67(95%CI 0.61, 0.73),优于临床病理模型和Oncotype DX复发评分。
  • 在未接受辅助化疗的亚组中,含BPE组合模型C-index为0.70,高于Oncotype DX复发评分的0.51。

核心结论

  • 乳腺癌诊断时的BPE是激素受体阳性、HER2阴性、腋窝淋巴结阴性患者iDFS的独立预测因素。

研究设计与样本

  • 单中心回顾性研究,纳入2015年1月至2024年1月间接受Oncotype DX复发评分检测的激素受体阳性、HER2阴性且无腋窝淋巴结转移的女性乳腺癌患者2190例(平均年龄49.2±9.2岁)。
  • 评估临床病理数据、乳腺MRI背景实质强化(BPE)和乳腺密度,分析iDFS相关因素并比较预测模型。

关键影像表现/征象

  • 肿瘤大小、组织学分级、淋巴血管侵犯和BPE与iDFS独立相关。

诊断标准与关键数值

  • 含BPE组合模型预测5年iDFS的C-index为0.64、AUROC为0.67(95%CI 0.61, 0.73)。
  • 临床病理模型预测5年iDFS的C-index为0.61、AUROC为0.63(95%CI 0.57, 0.69)。
  • Oncotype DX复发评分单独预测5年iDFS的C-index为0.55、AUROC为0.58(95%CI 0.52, 0.64)。
  • 接受辅助化疗亚组中,含BPE组合模型C-index为0.62,Oncotype DX复发评分C-index为0.55;未接受辅助化疗亚组中分别为0.70和0.51。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Background parenchymal enhancement (BPE) at breast MRI was associated with long-term survival in patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients. Oncotype DX Recurrence Score (RS) is used for prognostic prediction and adjuvant therapy decision-making.

PURPOSE: To identify clinicopathologic and radiologic features associated with invasive disease-free survival (iDFS) and to compare with the Oncotype DX RS.

METHODS: This single center, retrospective study included female patients with hormone receptor-positive, HER2-negative breast cancer and no axillary lymph node metastasis who underwent Oncotype DX RS testing between January 2015 and January 2024. Clinicopathologic data, BPE, and breast density were assessed. Factors associated with iDFS were analyzed and prediction models were compared.

RESULTS: 2,190 women (mean age 49.2 ± 9.2 [SD]) were included. Tumor size, histologic grade, lymphovascular invasion, and BPE were independently associated with iDFS. A combined BPE model that incorporated these factors demonstrated superior discrimination for 5-year iDFS (C-index: 0.64, AUROC: 0.67 [95 % confidence interval [CI]: 0.61, 0.73]) compared to the clinicopathologic model (C-index: 0.61, AUROC: 0.63 [95 % CI: 0.57, 0.69]) and Oncotype DX RS alone (C-index: 0.55, AUROC: 0.58 [95 % CI: 0.52, 0.64]). Subgroup analyses demonstrated that this improvement in predictive performance was observed both in patients who received adjuvant chemotherapy (C-index: 0.62 vs. 0.55) and in those who did not (C-index: 0.70 vs. 0.51).

CONCLUSION: BPE at the time of breast cancer diagnosis was an independent predictor of iDFS in patients with hormone receptor-positive, HER2-negative, and axillary node-negative breast cancer.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Cho SM, Eom HJ, Kim HJ, et al. Background parenchymal enhancement as a predictor of invasive disease-free survival in hormone receptor-positive, HER2-negative breast cancer. Eur J Radiol. 2025. PMID: 40743873. doi:10.1016/j.ejrad.2025.112340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。